Fundraising Fox
Renova Therapeutics
Carlsbad, US · 1 known investors
Find your way into Renova Therapeutics
Sign up to see every warm intro you have to Renova Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Renova Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Renova Therapeutics develops investigational gene therapies intended as single-dose, long-lasting treatments for common chronic diseases, with an initial focus on congestive heart failure and type 2 diabetes. The company builds a platform of therapeutics and delivery systems based on proprietary insights into disease mechanisms.
Founders & leadership
Board
Investors · 1
Funding
SEC filings, press & company announcements$166.5K disclosed across 1 of 2 rounds · 2014–2024
- Undisclosed amountSeries CNov 2014Source ↗
▶$166.5KraisedSep 2024 · 7 investors · BiotechnologyRule 506(b)
- Roy CosanDirector
- Pierre LecocqDirector
- Vijay MahantDirector
- Michael TorresDirector
- Kirk HammondDirector
- William DavidsonDirector
- Morgan XuDirector
- Shawn SwaneyExecutive Officer
- Offering amount
- $500K
- Amount sold
- $166.5K
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Renova Therapeutics.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2022 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $241.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2016 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2014 | $240.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Renova Therapeutics do?
- Renova Therapeutics develops investigational gene therapies intended as single-dose, long-lasting treatments for common chronic diseases, with an initial focus on congestive heart failure and type 2 diabetes. The company builds a platform of therapeutics and delivery systems based on proprietary insights into disease mechanisms.
- Who founded Renova Therapeutics?
- Renova Therapeutics was founded by Kirk Hammond.
- Who are Renova Therapeutics's investors?
- Renova Therapeutics's investors include BioBrit.
- How much funding has Renova Therapeutics raised?
- Renova Therapeutics has disclosed $166.5K raised across 1 of its 2 known rounds.
- Where is Renova Therapeutics headquartered?
- Renova Therapeutics is headquartered in Carlsbad, US.